AI-designed proteins outperform existing CAR T designs against BCMA tumors in mice

CAR T compartment therapy, which involves genetically modifying a patient's ain immune cells to combat cancer, is simply a method that has shown large promise, particularly against humor cancers. But currently, lone astir 4% of patients with precocious oregon metastatic crab successful the United States are candidates for CAR T therapy, and person to 3% volition really benefit, according to 1 caller analysis.